Resultados de la búsqueda 21-30 of 1215 for substance P
... P. prophylactic PLND Q. no prophylactic PLND. Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer. Rochester ...
To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by ...
Probiotics Preventing Immune Checkpoint Inhibitor-Induced Colitis · To evaluate the safety of multi-strain probiotic blend in cancer patients receiving ICIs. · To ...
To evaluate the safety of multi-strain probiotic blend in cancer patients receiving ICIs. · To evaluate the clinical outcomes related to IIC, including the ...
Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...
Rochester, Minn. The purpose of this study is to explore how using different terms (with or without the word cancer) to identify papillary thyroid cancer might ...
Although survivorship recommendations have been developed in areas such as lymphoma and stem cell transplant, the long-term effects of CAR-T therapy are ...
... P. prophylactic PLND Q. no prophylactic PLND. Numeración de páginas Estudios clínicos. AnteriorPágina anterior · Ir a página 22 · Ir a página 33 · Ir a página 4 ...
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?